Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$122.59 USD
-0.73 (-0.59%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $122.61 +0.02 (0.02%) 5:00 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SRPT 122.59 -0.73(-0.59%)
Will SRPT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Sarepta Therapeutics (SRPT) Down 4.7% Since Last Earnings Report: Can It Rebound?
Implied Volatility Surging for Sarepta (SRPT) Stock Options
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for SRPT
Sarepta Therapeutics Expands Incentive Plan, Shareholders Vote
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
Sarepta to replace ShockWave Medical in S&P 400 at open on 6/3
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Health Care Stocks Whale Activity In Today's Session